Merck shares data from phase 3 trial of Keytruda for gastric cancers
May 2, 2024Research and Development Gastric, MSD, Merck, Oncology, keytruda
Merck, known as MSD outside of the US and Canada, has announced data from the phase 3 KEYNOTE-811 trial which …
Verona Pharma to share phase 3 COPD trial data at ATS 2024
May 2, 2024Medical Communications COPD, Cardiology, clinical trial, verona pharma
Verona Pharma has announced that it will share eight posters at the American Thoracic Society International Conference (ATS) 2024, including …
Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration
May 1, 2024Manufacturing and Production Beckman Coulter Life Sciences, DNA, Pharmacy, RNA, Watchmaker Genomics, collaboration
Beckman Coulter Life Sciences and Watchmaker Genomics have announced that they have entered into a collaborative partnership with the aim …
Veru announces first patients enrolled in phase 2b trial for weight loss treatment
May 1, 2024Research and Development Obesity, Veru, Wegovy, enobosarm, weight loss
Veru has announced that it has enrolled the first patients into its phase 2b clinical trial of enobosarm, an oral …
Bayer and Evotec to collaborate on precision cardiology
April 30, 2024Research and Development Bayer, Cardiology, cardio, cvd
Bayer and Evotec have announced that they have updated the focus of their collaboration to work on the development of …
PeptiDream and Novartis extend peptide discovery collaboration
April 30, 2024Research and Development Novartis, PeptiDream, Pharmacy, collaboration, drug discovery, peptides
PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.
Pfizer’s Beqvez approved by FDA for haemophilia B treatment
April 29, 2024Medical Communications FDA, Haematology, Pfizer, haemophilia
Pfizer has announced that the US Food and Drug Administration (FDA) has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of …
J&J gains positive CHMP opinion for Rybrevant for treatment of lung cancer
April 29, 2024Medical Communications CHMP, EMA, J&J, Oncology, Rybrevant, lung cancer
Janssen, a Johnson & Johnson (J&J) company, has announced that the Committee for Medicinal Products for Human Use (CHMP) of …
Regeneron and Mammoth Biosciences announce CRISPR collaboration
April 26, 2024Research and Development Pharmacy, Regeneron, crispr, gene editing
Regeneron Pharmaceuticals and Mammoth Biosciences have announced a collaboration for the research, development and commercialisation of in vivo CRISPR-based gene …
ANGLE signs commercial agreement with AstraZeneca
April 26, 2024Business Services Angle, AstraZeneca, Pharmacy, commercial agreement
ANGLE has announced that it has signed a supplier agreement with AstraZeneca for the development and validation of a methodology …
Prism BioLab and Ono Pharmaceutical enter joint research and licensing agreement
April 25, 2024Research and Development Oncology, Ono Pharmaceutical, Prism BioLab, research and licensing agreement
Prism BioLab has announced that it has entered into a target-exclusive research and licensing agreement with Ono Pharmaceutical. Under the …
Ascendis Pharma’s Yorvipath approved by MHRA for hypoparathyroidism treatment
April 25, 2024Medical Communications Ascendis Pharma, Internal Medicine, MHRA, hypoparathyroidism
Ascendis Pharma has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation for Yorvipath …
Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals
April 24, 2024Manufacturing and Production Eli Lilly, Nexus Pharmaceuticals, Pharmacy, acquisition, facility
Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement for Eli Lilly to acquire …
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
April 24, 2024Medical Communications FDA, GSK, Oncology, endometrial cancer, sBLA
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for …
Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia
April 23, 2024Research and Development Cardiology, Sanofi, clinical trial, thrombocytopenia
Sanofi has announced positive results from its phase 3 LUNA 3 study, which assessed rilzabrutinib 400mg twice daily oral treatment …
FDA approves ImmunityBio’s Anktiva bladder cancer treatment
April 23, 2024Medical Communications Anktiva, FDA, ImmunityBio, Oncology, bladder cancer
ImmunityBio has announced that the US Food and Drug Administration (FDA) has approved Anktiva (N-803, or nogapendekin alfa inbakicept-pmln) plus …
EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment
April 22, 2024Medical Communications Emblaveo, European Commission, Immunology, Pfizer
Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Emblaveo (aztreonam-avibactam) for the treatment of adult …
Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder
April 22, 2024Research and Development Kaerus Bioscience, Neurolentech, Neurology, neurodevelopmental disorders, neurology
Neurolentech has announced that it has entered into a technology access partnership with Kaerus Bioscience, with the aim of driving …
Ardena announces €20m expansion following first GMP approval
April 19, 2024Manufacturing and Production Ardena, Pharmacy, facility, manufacturing
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new …
Roche’s Alecensa approved by FDA as lung cancer treatment
April 19, 2024Medical Communications FDA, Oncology, Roche, lung cancer
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
